SLC5A2 and atrial fibrillation: Analyses for subgroups of interest of patients with HFpEF likely to be at higher risk of AF (particularly those with older age or obesity) similarly indicated a consistent benefit with SGLT2 inhibitors and no apparent heterogeneity between empagliflozin and dapagliflozin [15].